Skip to content
Scintria
ToolsGrant writerFunding
HomeLiteratureClinical trialsEvidence LabProtocol packData analysisLearnProjectsLibraryReferencesApplications
Start free
ScintriaStart free

Learn / Clinical Research Management / Close-out, transparency and professional practice

Transparency: registration, results and publication

12 minute read · 6-question quiz

Download this lesson as a colour Word or PDF study guide with the figures and answers. Included in paid plans; reading and quizzes stay free.Sign in

What you will learn

  • Explain why trials must be registered and results shared

  • Name the main trial registries and when registration is due

  • Apply authorship and publication ethics (ICMJE) and data sharing principles

Trial results belong to participants and the public as well as to sponsors. Without transparency, only positive results are published and clinicians make decisions on incomplete evidence, a problem known as publication bias.

Registration

Registering a trial in a public registry before the first participant is enrolled records the question, design and planned outcomes, so that later changes can be seen.

  • ClinicalTrials.gov (United States).
  • WHO International Clinical Trials Registry Platform (ICTRP), which gathers records from national and regional registries.
  • Pan African Clinical Trial Registry (PACTR), widely used in Africa.
  • EU Clinical Trials Register and others.

The International Committee of Medical Journal Editors (ICMJE) requires prospective registration as a condition of publishing in member journals. Many regulators and funders also require it.

Results reporting

  • Results summaries must be posted in registries within the period set by law or policy (for example, within 12 months of completion in several systems; check current requirements).
  • The clinical study report goes to regulators.
  • Lay summaries make results accessible to participants and the public.
  • Negative and inconclusive results must be reported too.
Before enrolmentRegister the trialDuringUpdate status andamendmentsAt completionNotify regulators andethicsRequired periodPost resultsAfterPublish and share withparticipants
Transparency steps from registration to publication.

Authorship and publication ethics

The ICMJE criteria say an author must meet all four:

  1. Substantial contributions to design, data collection, analysis or interpretation.
  2. Drafting or critically revising the work.
  3. Final approval of the version to be published.
  4. Accountability for all aspects of the work.

Others who contribute (for example, data entry staff or an editor) are acknowledged. Ghost authorship (a hidden writer) and gift authorship (an author with no real contribution) are misconduct. Sponsors should not control the content of publications in ways that hide results, and contracts should protect the right to publish.

The CONSORT statement guides reporting of randomised trials, with a flow diagram of participants, and SPIRIT guides protocol content. Conflicts of interest and funding must be disclosed.

Data sharing

Sharing de-identified participant data, with proper governance, allows others to verify and re-use results. Data sharing plans, consent wording and privacy protections should be designed from the start.

Worked example: unreported trials and the evidence

A hypothetical review finds 40 registered trials of a new antidepressant. 25 show benefit and 15 do not. Only 22 of the 25 positive trials and 4 of the 15 negative ones are published.

  • Published trials: 22 + 4 = 26, of which 22 are positive, or 85%.
  • Actual share positive: 25 / 40 = 63%.

Anyone reading only the published literature would think the drug works much better than the complete data show. Registration and results reporting make missing trials visible.

020406080Share showing benefit (%, illustrative)63All registered trials85Published trials only
Illustrative numbers: selective publication inflates the apparent benefit.

Honest reporting is a duty to participants

People accepted risk to produce knowledge. Failing to report their trial wastes their contribution.

Do not change the primary outcome after seeing the data

Switching outcomes after results are known is a form of misreporting. Compare reports with the registered protocol and explain any changes.

Check yourself

Find the registry record of a trial you know. Does the publication report the same primary outcome?

Summary

  • Trials are registered before enrolment and results are reported in registries and publications.

  • ClinicalTrials.gov, WHO ICTRP and PACTR are major registries; ICMJE requires prospective registration.

  • Authorship requires all four ICMJE criteria; ghost and gift authorship are misconduct.

  • Reporting negative results and sharing data support trustworthy evidence.

Check your understanding

Question 1
1

When should a trial be registered?

Question 2
2

PACTR is the:

Question 3
3

Ghost authorship means:

Question 4
4

Of 40 registered trials, 22 positive and 4 negative are published. The positive share among published trials is:

Question 5
5

CONSORT is a guideline for reporting:

Question 6
6

Publication bias occurs when:

Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.

Trial and site close-outProfessional practice, careers and a culture of quality